Hugo A. Armelin
YOU?
Author Swipe
View article: RASGRP4 is a key factor in KRAS activation mediated by SOS in Y1 mouse tumor cell line
RASGRP4 is a key factor in KRAS activation mediated by SOS in Y1 mouse tumor cell line Open
The Y1 mouse adrenocortical carcinoma cell line presents amplification of the KRas oncogene and high-basal levels of KRAS-GTP mediated by the GEF SOS. In this research, we developed a dynamic model based on ordinary differential equations …
View article: Figure S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S5: Combined toxicity of LB-100 and Adavosertib in PDAC and CCA models (A) and (B) Dose-response assays show the effect of LB-100 or Adavosertib in 4 PDAC and 4 CCA models, respectively. Cell viability was estimated by resazurin flu…
View article: Table S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Table S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Supplementary table 5: Stress-focused drug screens AUC differences in HT-29 cells Area Under the Curve (AUC) from each compound of the stress-focused drug screen in the presence or absence of LB-100. Compounds are ranked by the difference …
View article: Data from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Data from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogeni…
View article: Figure S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S1: LB-100 engages stress-related, inflammatory response, and mitogenic signaling transcriptional programs in CRC cells (A) Dose-response assays show the effect of LB-100 in 7 CRC models. Cell viability was estimated by resazurin fl…
View article: Data from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Data from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Cancer homeostasis depends on a balance between activated oncogenic pathways driving tumorigenesis and engagement of stress response programs that counteract the inherent toxicity of such aberrant signaling. Although inhibition of oncogeni…
View article: Figure S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S1: LB-100 engages stress-related, inflammatory response, and mitogenic signaling transcriptional programs in CRC cells (A) Dose-response assays show the effect of LB-100 in 7 CRC models. Cell viability was estimated by resazurin fl…
View article: Figure S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S1: LB-100 engages stress-related, inflammatory response, and mitogenic signaling transcriptional programs in CRC cells (A) Dose-response assays show the effect of LB-100 in 7 CRC models. Cell viability was estimated by resazurin fl…
View article: Figure S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S2 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S1: LB-100 engages stress-related, inflammatory response, and mitogenic signaling transcriptional programs in CRC cells (A) Dose-response assays show the effect of LB-100 in 7 CRC models. Cell viability was estimated by resazurin fl…
View article: Table S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Table S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Supplementary table 7: Full list of genes whose knockout was selectively toxic in the presence of LB-100 in SW-480 cells in the CRISPR-KO screen FDR smaller or equal to 0.25 and log2 fold change smaller or equal to -1 in treated/untreated …
View article: Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Supplementary table 3: Full list of genes whose knockout attenuated LB-100 toxicity in SW-480 cells in the CRISPR-KO screen FDR smaller or equal to 0.25 and log2 fold change greater or equal to 1 in treated/untreated comparison were criter…
View article: Figure S10 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S10 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S10: Acquired resistance to the combination of LB-100 and Adavosertib suppress anchorage-independent and tumor growth in CRC models (A) Endpoint proliferation of HT-29 and SW-480 parental and resistant cells growing attached or in a…
View article: Figure S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S4: Combined toxicity of LB-100 and Adavosertib in CRC models (A) Dose-response assays show the effect of Adavosertib in 7 CRC models. Cell viability was estimated by resazurin fluorescence after 5 days in the presence of the drug o…
View article: Table S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Table S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Supplementary table 7: Full list of genes whose knockout was selectively toxic in the presence of LB-100 in SW-480 cells in the CRISPR-KO screen FDR smaller or equal to 0.25 and log2 fold change smaller or equal to -1 in treated/untreated …
View article: Table S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Table S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Supplementary table 4: The composition of the stress-focused drug library Compounds comprising the stress-focused drug library with their respective targets.
View article: Figure S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S7: Normal tissues from the orthotopic CRC PDXs are not affected by LB-100, adavosertib, or the combination. Representative Hematoxylin & Eosin (H&E) stainings of the heart, liver, lung, and spleen from the PDOX1 PDXs treated as ind…
View article: Table S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Table S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Supplementary table 1: Cancer cell lines with oncogenic drivers The mutational status of the cell lines was compiled from the ATCC, Catalogue of Somatic Mutations in Cancer (COSMIC) and Cell Model Passport, Wellcome Trust Sanger Institute,…
View article: Figure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S8: Acquired resistance to the combination of LB-100 and adavosertib suppressed malignant traits in CRC models (A) IncuCyte-based proliferation assays from HT-29 and SW-480 parental and resistant cells in the absence or presence of …
View article: Figure S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S6: LB-100 and adavosertib induce histological response in orthotopic CRC PDXs (A) Representative Hematoxylin & Eosin (H&E) stainings at endpoint from PDOX2 and PDOX3 treated as indicated. Original magnification middle images: 15x, …
View article: Figure S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S3: High N-Myc levels sensitize neuroblastoma cells to LB-100, and PP2A knockdown sensitizes CRC cells to WEE1 inhibition (A) Western blots comparing N-Myc levels in isogenic neuroblastoma models. GAPDH was used as a loading control…
View article: Table S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Table S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Supplementary table 6: Stress-focused drug screens AUC differences in SW-480 cells Area Under the Curve (AUC) from each compound of the stress-focused drug screen in the presence or absence of LB-100. Compounds are ranked by the difference…
View article: Table S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Table S5 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Supplementary table 5: Stress-focused drug screens AUC differences in HT-29 cells Area Under the Curve (AUC) from each compound of the stress-focused drug screen in the presence or absence of LB-100. Compounds are ranked by the difference …
View article: Figure S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S4 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S4: Combined toxicity of LB-100 and Adavosertib in CRC models (A) Dose-response assays show the effect of Adavosertib in 7 CRC models. Cell viability was estimated by resazurin fluorescence after 5 days in the presence of the drug o…
View article: Figure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S8 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S8: Acquired resistance to the combination of LB-100 and adavosertib suppressed malignant traits in CRC models (A) IncuCyte-based proliferation assays from HT-29 and SW-480 parental and resistant cells in the absence or presence of …
View article: Figure S10 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S10 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S10: Acquired resistance to the combination of LB-100 and Adavosertib suppress anchorage-independent and tumor growth in CRC models (A) Endpoint proliferation of HT-29 and SW-480 parental and resistant cells growing attached or in a…
View article: Figure S9 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S9 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S9: Single-cell RNAseq identify transcriptional signatures downregulated in CRC cells after acquired resistance to the combination of LB-100 and adavosertib UMAP representations of HT-29 (A) and SW-480 (B) cells colored by the activ…
View article: Figure S9 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S9 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S9: Single-cell RNAseq identify transcriptional signatures downregulated in CRC cells after acquired resistance to the combination of LB-100 and adavosertib UMAP representations of HT-29 (A) and SW-480 (B) cells colored by the activ…
View article: Figure S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Figure S7 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Figure S7: Normal tissues from the orthotopic CRC PDXs are not affected by LB-100, adavosertib, or the combination. Representative Hematoxylin & Eosin (H&E) stainings of the heart, liver, lung, and spleen from the PDOX1 PDXs treated as ind…
View article: Table S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Table S6 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Supplementary table 6: Stress-focused drug screens AUC differences in SW-480 cells Area Under the Curve (AUC) from each compound of the stress-focused drug screen in the presence or absence of LB-100. Compounds are ranked by the difference…
View article: Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy
Table S3 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy Open
Supplementary table 3: Full list of genes whose knockout attenuated LB-100 toxicity in SW-480 cells in the CRISPR-KO screen FDR smaller or equal to 0.25 and log2 fold change greater or equal to 1 in treated/untreated comparison were criter…